Clinical Trials Update: Feb. 21, 2007
Skin Cancer Unverricht-Lundborg Syndrome Diabetic Neuropathy
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This trial will compare Allovectin-7 vs. chemotherapy in people with stage 3 or stage 4 melanoma. Volunteers may qualify if they are at least 18, have confirmed stage 3 or stage 4 melanoma that may have had previous treatment, and at least one melanoma tumor that is 1cm x 1cm or greater (about the size of a dime). People with melanoma lesions in the brain or liver will not be eligible.
The research sites are located across the United States.
This trial is for people with Unverricht-Lundborg Disease (ULD), a genetic form of progressive epilepsy that causes movement disorders (myoclonus) and seizures. The trial will test the effectiveness and safety of different doses of a new medication in reducing myoclonus and improving overall function. Candidates 16 or older with diagnosed ULD ascertained by appropriate genetic testing may be eligible.
The research sites are located in Italy and France.
This study will evaluate the safety and effectiveness of an investigational medication vs. placebo to treat diabetic peripheral neuropathy. Patients 18-75 diagnosed with type 1 or type 2 diabetes who are on stable doses of diabetic medication may be eligible.
The research site is in Palm Beach Gardens, Fla.
Copyright 2007 Thomson CenterWatch. All rights reserved.